Business Description
Pfizer is a global pharmaceutical company specializing in the comprehensive research, development, production, and marketing of prescription medications, vaccines, and healthcare solutions. The company’s therapeutic expertise includes cancer, immunology, cardiology, and vaccines. Pfizer’s primary focus is on pharmaceutical development, continually innovating to meet global health needs through revolutionary pharmaceuticals and preventive healthcare solutions (Pfizer, 2023). This dedication places Pfizer at the forefront of medical knowledge, serving essential sectors and significantly improving global well-being and healthcare outcomes.
Business Case
Pfizer chooses to finance R&D internally to avoid financial concerns and preserve autonomy. The goal of this strategy is total control over choices and resources. Relying solely on internal funding might slow innovation and make it harder to respond quickly to healthcare demands, even while it guarantees independence.
To maintain Pfizer’s leadership in the healthcare industry, I propose spearheading a $500 million initiative encompassing research, trials, manufacturing, and compliance for innovative vaccines. Pfizer is seeking $500 million in financing for an ambitious research and development project to develop a novel vaccine for a common infectious illness. This all-inclusive budget includes $200 million for research activities, $150 million for clinical trials, $100 million for the setup of a manufacturing facility, and $50 million for regulatory compliance.
Pfizer has several financing options, including borrowing, issuing shares, self-funding, and partnering with capital firms (Alkhyeli et al., 2021). While self-funding offers autonomy, it may also limit the funds available for large-scale initiatives. While debt financing allows quick access to funds, it also entails interest payments that may hurt cash flows (The Wall Street Journal, 2024). Equity financing offers money without debt commitments but may weaken shareholder equity and control (Alkhyeli et al., 2021). Collaboration with venture capital companies can provide project-specific cash and expertise, but it may result in loss of control and profit-sharing.
Evaluating the requirements and risks associated with each financing source is critical. Self-funding may limit cash available, thereby impeding larger-scale ventures. Debt funding requires satisfying interest commitments but has a lesser risk of diluting ownership. Equity financing eliminates debt but risks diminishing current owners’ power (Alkhyeli et al., 2021). Venture finance provides knowledge and resources in exchange for control and profit share.
Given Pfizer’s current financial health, with a significant debt-to-equity ratio but an excellent current ratio suggesting short-term liquidity, debt financing appears prudent. It provides needed financing without diluting ownership right away. Nonetheless, strategic debt management is necessary to lessen the financial strain of interest payments. Pfizer has chosen a 100% self-funding strategy to retain high control and strategic mobility in its innovation activities (Alkhyeli et al., 2021). This decision aligns with the business’s objective of promoting innovation and guaranteeing financial independence.
Moreover, APRs are expected to be 3-5% for short-term debt and 4-6% for long-term debt, as seen in Table 2 (Yahoo! Finance, 2024). Despite interest payments, equity financing (8–10%) is more expensive, making debt financing a more practical option (The Wall Street Journal, 2024). Debt funding looks to be the best option for sustainability, given Pfizer’s financial situation and R&D requirements. Furthermore, Pfizer’s Weighted Average Cost of Capital (WACC: 6.98%) and Cost of Equity (7.84%), computed using the Capital Asset Pricing Model and WACC methodology, are shown in Table 1 (AlphaSpread, 2024).
Table 1 – Cost of Equity and WACC for Pfizer (PFE)
Table 2 – Estimated Annual Percentage Rates (APRs) for Funding Sources
Profit and Loss Statement for Pfizer Inc.
Table 3 – Profit and Loss Statement for Pfizer Inc. (Amounts in billions USD)
Pfizer’s expected financial performance over the next three years is outlined in Table 3. It contains information on the business’s earnings. It includes gross and net operating revenue, other operating revenues, total revenues (including other income), cost of materials consumed, employee benefits, financing costs, depreciation, and other expenses. It also has total outlays, profit before taxes, tax expenses, and net profit (Yahoo! Finance, 2024). The table gives a thorough overview of Pfizer’s financial activities and net profit for the given time frame.
Table 4 – Direct Cost Estimates for Pfizer Inc.
Pfizer’s estimated direct expenses over three years are shown in Table 4, along with key operational spending areas. Capital expenses show a regular budget for the upkeep of the asset. The company’s ever-rising marketing costs demonstrate its commitment to outreach. Changes in the workforce are causing a slight increase in labor expenses. Even if they vary slightly, supply costs are continuous operational costs. These projections provide vital information on Pfizer’s resource allocation to support informed financial planning and sustained operational effectiveness.
References
Alkhyeli, S., Abdulla, F., Alshehhi, A., Aldhaheri, N., Alhosani, M., Alsereidi, A., Al Breiki, M., & Nobanee, H. (2021). Financial Analysis and performance evaluation of Pfizer. SSRN Electronic Journal.
AlphaSpread. (2024). Pfizer Inc (NYSE:PFE). AlphaSpread.com.
Pfizer. (2023). Pfizer’s financial performance in 2022. Pfizer’s financial performance in 2022 | Pfizer 2022 Annual Report.
The Wall Street Journal. (2024). Pfizer Inc. PFE (U.S.: NYSE).
Yahoo! Finance. (2024). Pfizer Inc. (PFE) valuation measures & financial statistics.